Registry for Endovascular Treatment of Acute Ischemic Stroke
Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study （OCIN-AIS-EVT REGISTRY）
This study is trying to see how safe and effective a specific treatment for stroke is in helping patients recover after a blocked blood vessel.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Sex | All |
| Sponsor | Changhai Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT05864638 on ClinicalTrials.gov |
What this trial studies
The OCIN-AIS-EVT REGISTRY is a prospective, multicenter observational trial designed to evaluate the safety and functional outcomes of endovascular treatment for acute ischemic stroke caused by vessel occlusion. This study will assess patients undergoing intravascular therapy and will measure outcomes using the modified Rankin scale at 90 days post-treatment. By collecting data from multiple centers, the registry aims to reflect routine clinical practice and provide insights into the effectiveness of these interventions.
Who should consider this trial
Good fit: Ideal candidates are individuals experiencing acute ischemic stroke due to vessel occlusion in either the anterior or posterior circulation.
Not a fit: Patients who do not have acute ischemic stroke or those who are not eligible for intravascular therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment protocols and outcomes for patients suffering from acute ischemic stroke.
How similar studies have performed: Other studies have shown promising results with endovascular treatments for acute ischemic stroke, indicating a potential for success in this registry approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Acute ischemic stroke caused by anterior or posterior circulation vessel occlusion confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA) or digital subtraction angiography (DSA) 2. Undergo intravascular therapy (i.e. access to a cath lab and an arterial puncture) 3. The patient or his/her legal representative agreed to participate in the study and has signed the informed consent. Exclusion Criteria: 1\) No exclusion criteria
Where this trial is running
Shanghai
- Jianimin Liu — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Jianimin Liu, M.D. — Changhai Hospital
- Study coordinator: Pengfei Yang, M.D.
- Email: 15921196312@163.com
- Phone: 86-21-31161784
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.